Transplant News and Research

RSS

Micromet initiates MT103 phase 2 trial in adult ALL patients

Micromet, Inc. today announced the initiation of a phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab is the first of a new class of agents called BiTE antibodies, designed to harness the body's T cells to kill cancer cells.

20 Sep 2010

UCLA conference to provide information about latest developments to help enhance quality of life of seniors

While aging impacts everyday living in many ways, the latest technologies in the medical, consumer and lifestyle fields have the potential to help older adults live better for longer.

18 Sep 2010

New genetic analysis technique isolates culprit gene in families with inherited single-gene kidney diseases

A University of Michigan-led research team has identified a gene responsible in some families for a devastating inherited kidney disorder, thanks to a new, faster method of genetic analysis not available even two years ago. The success offers hope that scientists can speed the painstaking search for the genes responsible for many rare diseases and test drugs to treat them.

17 Sep 2010

Scientists discover protein to regulate blood stem cells’ activity for leukemia treatment

A discovery made by Dr. Tarik Möröy, President and Scientific Director and Director of the IRCM, and his team was recently published in Blood, the official journal of the American Society of Hematology. The researchers found that a protein can regulate certain characteristics of blood stem cells, which could lead to a better treatment for leukemia patients.

17 Sep 2010

bluebird bio publishes LentiGlobin gene therapy clinical trial data results

bluebird bio an emerging leader in the development of innovative gene therapies for severe genetic disorders, today announced publication in the journal Nature of its promising Phase 1/2 data highlighting positive results of LentiGlobin gene therapy treatment in a young adult with severe beta-thalassemia, a blood disorder that is one of the most frequent inherited diseases.

16 Sep 2010

Chimerix presents promising clinical data for CMX001 in late-breaker poster session at 50th ICAAC

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today presented promising clinical data for CMX001 in a late-breaker poster session at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy.

16 Sep 2010

Renal research consortia receives two grants for translational research from DKF

The Dutch Kidney Foundation (DKF) awards two Consortium Grants of 1,5 million euro to renal research consortia to concentrate on translational research.

16 Sep 2010

FDA updates dosing recommendation for Valcyte medication

The U.S. Food and Drug Administration is notifying health care professionals of updated dosing recommendations for Valcyte (valganciclovir) oral tablets and solution used by children and adolescents receiving a kidney or heart transplant.

16 Sep 2010

Scientists reveal techniques to extend organ transplant life

Experts from the Medical Research Council (MRC) Centre for Transplantation at King's College London, based at Guy's Hospital, have revealed exciting new scientific developments for people with an organ transplant, intended to help prevent rejection of the new organ and extend its life.

16 Sep 2010

Virus related organ recipient deaths to be examined

After the death of three organ transplant recipients, a Victorian coroner will examine if it is possible to screen for a particular virus before donation.

15 Sep 2010

UK HealthCare announces successful kidney transplant surgery in 16-year-old

UK HealthCare announces the revitalization of its pediatric kidney transplant program with the successful transplant surgery of 16-year-old Courtney Stroud, of Carlisle, Ky. Courtney's transplant was performed Aug. 31 at Kentucky Children's Hospital.

15 Sep 2010

ThermoGenesis 2010 fourth quarter revenue increases to $7.2 million

ThermoGenesis Corp., a leading supplier of innovative products and services that process and store adult stem cells, said today that revenues for the fourth quarter of fiscal 2010 were $7.2 million versus revenues of $4.0 million for the same quarter a year ago. Revenues in the third quarter of fiscal 2010 were $4.8 million.

15 Sep 2010

ThermoGenesis retains compliance with NASDAQ listing standards

ThermoGenesis Corp. a leading supplier of innovative products and services that process and store adult stem cells, said today that it has been informed by NASDAQ that the Company is in compliance with all NASDAQ listing standards, including the minimum price bid requirement.

14 Sep 2010

Cell-enriched primary renal cells improve survival and augment kidney function in CKD rodents

Tengion, Inc., a leader in regenerative medicine, announced today the publication of a key study in the American Journal of Physiology Renal Physiology by researchers at Tengion. In the study, rodents with chronic kidney disease (CKD) were treated with healthy kidney cells to catalyze the regeneration of functional kidney tissue and delay disease progression, as evidenced by extended survival, improved kidney filtration, and reduced severity of kidney tissue pathology.

14 Sep 2010

Human cytomegalovirus cloned

A team of Welsh scientists have successfully cloned a human virus offering new hope for the treatment of potentially life-threatening diseases.

14 Sep 2010

Study finds new therapeutic target for polycystic kidney disease

In work suggesting a new approach to treating polycystic kidney disease (PKD), a leading cause of kidney failure, researchers at Children's Hospital Boston were able to block the formation of fluid-filled cysts, the hallmark of the disease, in a mouse model. Their findings, using a compound that inhibits a receptor known as c-Met, will be published in the September 13th online edition of the Journal of Clinical Investigation.

14 Sep 2010

Pharmacyclics reports $9.3 million increase in total revenue for 2010 fiscal year

Pharmacyclics, Inc. today reported financial results for its fiscal year and fourth quarter which ended June 30, 2010.

14 Sep 2010

Vical's TransVax CMV vaccine achieves key endpoints in Phase 2 trial in immunocompromised HCT recipients

Vical Incorporated announced today the achievement of key efficacy, immunogenicity and safety results in a Phase 2 trial, establishing its TransVax™ cytomegalovirus (CMV) vaccine as the first to provide evidence of protection in immunocompromised hematopoietic cell transplant (HCT) recipients, and defining a potential pathway for further development.

13 Sep 2010

Genzyme Corporation enters into asset purchase agreement with LabCorp

Genzyme Corporation today announced that it has entered into an asset purchase agreement under which Laboratory Corporation of America Holdings (LabCorp) will acquire Genzyme Genetics for $925 million in cash.

13 Sep 2010

Leukemia survivor to meet donor of bone marrow transplant

Ann Marie Del Fiacco, a 38-year-old Berwyn mother of two, owes her life to a stranger who volunteered to be a donor for her life-saving bone marrow transplant.

13 Sep 2010

Transplant News and Research

Micromet initiates MT103 phase 2 trial in adult ALL patients

UCLA conference to provide information about latest developments to help enhance quality of life of seniors

New genetic analysis technique isolates culprit gene in families with inherited single-gene kidney diseases

Scientists discover protein to regulate blood stem cells’ activity for leukemia treatment

bluebird bio publishes LentiGlobin gene therapy clinical trial data results

Chimerix presents promising clinical data for CMX001 in late-breaker poster session at 50th ICAAC

Renal research consortia receives two grants for translational research from DKF

FDA updates dosing recommendation for Valcyte medication

Scientists reveal techniques to extend organ transplant life

Virus related organ recipient deaths to be examined

UK HealthCare announces successful kidney transplant surgery in 16-year-old

ThermoGenesis 2010 fourth quarter revenue increases to $7.2 million

ThermoGenesis retains compliance with NASDAQ listing standards

Cell-enriched primary renal cells improve survival and augment kidney function in CKD rodents

Human cytomegalovirus cloned

Study finds new therapeutic target for polycystic kidney disease

Pharmacyclics reports $9.3 million increase in total revenue for 2010 fiscal year

Vical's TransVax CMV vaccine achieves key endpoints in Phase 2 trial in immunocompromised HCT recipients

Genzyme Corporation enters into asset purchase agreement with LabCorp

Leukemia survivor to meet donor of bone marrow transplant

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News